A nine-amino-acid "sleep peptide" discovered nearly fifty years ago whose gene has never been found, whose receptor has never been identified, and whose leading scientific review calls it "a still unresolved riddle"

In 1977, Swiss researchers Marcel Monnier and Georges Schoenenberger extracted a nine-amino-acid peptide from the cerebral venous blood of rabbits that had been electrically induced to sleep. They named it delta sleep-inducing peptide—DSIP—after the slow-wave delta brain activity it appeared to promote. It was a textbook moment in neuroscience: an endogenous sleep factor, isolated and sequenced. The expectation was that DSIP would quickly become as well-understood as other neuropeptides of its era.

That did not happen. Nearly fifty years later, no one has identified the gene that encodes DSIP, the precursor protein it is cleaved from, or the specific receptor it acts through. The 2006 review by Kovalzon in the Journal of Neurochemistry—the most comprehensive assessment ever published—called the sleep-inducing hypothesis "extremely poorly documented and still weak" and described DSIP as "a still unresolved riddle."

What has been documented is a set of pharmacological activities that do not obviously connect to each other: DSIP triggers calcium-dependent release of met-enkephalin from brainstem slices, suppresses ACTH and cortisol under stress, upregulates antioxidant enzymes, and modestly improves sleep efficiency in small double-blind studies. It may not work through a single mechanism at all—its effects may be entirely indirect, mediated through endorphin release and stress hormone suppression rather than through a dedicated DSIP signaling pathway that simply has not been found because it does not exist.

Quick Facts: DSIP at a Glance

What Is DSIP?

Pronunciation: D-S-I-P (dee-sip)

Your brain produces dozens of neuropeptides that regulate sleep, arousal, pain, stress, and mood. Most of them—orexin, NPY, galanin, substance P—have been sequenced, cloned, genetically characterized, and mapped to specific receptor systems within years of their discovery. Their genes are known, their precursor proteins are known, and their receptors are drug targets with billion-dollar pharmaceutical programs behind them.

DSIP is the exception. Discovered in 1977, it has resisted nearly fifty years of molecular characterization. It is one of the oldest known neuropeptides and one of the least understood.

The peptide is nine amino acids long (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu), approximately 850 daltons, and is found in the hypothalamus, pituitary gland, limbic system, and peripheral blood. It co-localizes with ACTH, CLIP, and MSH in the pituitary, suggesting a neuroendocrine role. It crosses the blood-brain barrier via a non-competitive, saturable transport mechanism (PMID 6547363), confirming it functions as a signaling molecule between the periphery and the CNS.

The fundamental mystery is structural: no gene encoding DSIP has been identified in any genome. No precursor protein that would be cleaved to release DSIP has been found. No receptor specific to DSIP has been cloned. For a peptide discovered in the same decade as enkephalins and endorphins—whose biology was resolved within years—this is extraordinary.

Origins and Discovery

In 1977, Marcel Monnier and Georges Schoenenberger at the University of Basel electrically stimulated the thalamus of rabbits to induce synchronized slow-wave (delta) sleep. They then collected cerebral venous blood from the sleeping animals, extracted a peptide fraction, and demonstrated that injecting this fraction into recipient rabbits induced delta sleep. The active peptide was sequenced: Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu.

The discovery generated intense interest. A "sleep factor"—a molecule that the sleeping brain releases into the bloodstream to promote sleep—was exactly the kind of finding that neuroscience had been looking for. Research groups across Europe and the United States launched programs to characterize DSIP's biology, clone its gene, and develop it therapeutically.

Within a decade, those programs had produced a paradox. DSIP clearly had biological effects—it modulated sleep, stress hormones, pain, and antioxidant systems in multiple labs. But the basic molecular biology was intractable. The gene could not be found. The receptor could not be cloned. The precursor protein could not be identified. Graf and Kastin at Tulane/VA showed that DSIP in blood existed primarily in a bound form that could be released by tryptic digestion—suggesting it might be a degradation product of a larger, unidentified carrier protein rather than a product of its own gene.

Research activity peaked in the 1980s and 1990s and has largely ceased, with the exception of occasional animal studies and a 2024 fusion-peptide BBB delivery study. DSIP remains one of neuroscience's most enduring unsolved puzzles.

Mechanism of Action

DSIP's mechanism is genuinely unresolved after nearly fifty years. Multiple pharmacological activities have been demonstrated, but no unified mechanism exists.

Endogenous Opioid System Modulation

DSIP stimulates the release of met-enkephalin from brainstem slices in vitro in a calcium-dependent manner (Nakamura et al. 1989). This is a critical finding: DSIP does NOT bind opioid receptors directly—it triggers the release of the brain's own opioid peptides. This may explain both the sleep-promoting effects (endorphin-mediated relaxation and pain suppression) and the addiction withdrawal efficacy (substituting endogenous opioid release for exogenous opioid dependence).

HPA Axis Modulation (Stress Response)

DSIP consistently lowers baseline ACTH levels and blunts the ACTH/cortisol surge during stress. It co-localizes with ACTH, CLIP, and MSH in the pituitary, suggesting direct neuroendocrine modulation. This "stress-limiting" activity may be DSIP's most pharmacologically significant mechanism and the primary basis for its sleep-promoting effects—reduced cortisol at night facilitates sleep onset and maintenance.

Antioxidant Upregulation

Animal studies show DSIP upregulates endogenous antioxidant enzymes—superoxide dismutase (SOD), catalase, and glutathione peroxidase. One study demonstrated that DSIP pretreatment completely prevented hypoxia-induced damage to mitochondrial respiration in rats. This neuroprotective activity may be independent of the sleep and opioid mechanisms.

Sleep Architecture Modulation

The original discovery showed DSIP promotes delta (slow-wave) sleep in rabbits. Human polysomnography confirmed improvements in sleep efficiency and sleep latency. However, the mechanism is indirect—DSIP does not appear to act through a dedicated sleep receptor. Sleep improvement may be secondary to cortisol suppression and endorphin release.

The Unresolved Riddle (Kovalzon 2006)

The Kovalzon review (PMID 16539679) concluded that "the link between DSIP and sleep has never been further characterized" and the sleep-inducing hypothesis is "extremely poorly documented and still weak." DSIP may be a fragment of a larger, unidentified signaling molecule, or its effects may be entirely mediated through indirect pathways.

Key Research Areas and Studies

Sleep Optimization

DSIP's primary marketed use is sleep improvement, based on two double-blind trials from the 1980s. Schneider-Helmert (1987, PMID 3622582) studied 14 chronic insomniacs with IV DSIP for 7 nights and found sleep efficiency normalized to control levels, with effects maintained post-treatment. Bes et al. (1992, PMID 1299794) studied 16 chronic insomniacs and found higher sleep efficiency and shorter sleep latency, but concluded that effects were "weak" and DSIP is "not likely to be of major therapeutic benefit."

Addiction Withdrawal

Dick et al. (1984, PMID 6548969) studied 107 inpatients—60 opiate-dependent and 47 alcohol-dependent—treated with IV DSIP. Results were striking: 97% of opiate-dependent patients and 87% of alcohol-dependent patients reported symptom improvement. These results are remarkable but must be evaluated against the study's fatal limitation: no control group, no blinding. Placebo response rates in addiction withdrawal studies are notoriously high. This study has never been replicated.

Stress Modulation

Animal studies demonstrate DSIP's stress-limiting capacity—blunting the cortisol surge, maintaining homeostasis under physical and psychological stress, and preventing stress-induced tissue damage. This may be the most clinically relevant mechanism.

Fifty Years Without a Gene—What Does That Mean?

DSIP's deepest mystery is molecular: no gene, no receptor, no precursor protein, despite nearly fifty years of searching. This is not a gap in funding or interest—multiple research groups on three continents attempted these characterizations. What does the failure to find them mean?

Possibility 1: DSIP is a degradation fragment. It may not have its own gene because it is a breakdown product of a larger, unidentified protein. Graf and Kastin's observation that DSIP circulates in a bound form (released by tryptic digestion) supports this. DSIP may be biologically active by accident—a fragment that happens to modulate enkephalin release and cortisol.

Possibility 2: The gene exists but is unlike conventional neuropeptide genes. DSIP's sequence (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) is not unusual, but the lack of a signal peptide or traditional prepropeptide structure may make the gene unrecognizable by standard cloning methods.

Possibility 3: DSIP is an artifact of the original extraction. Some researchers have questioned whether DSIP is truly an endogenous peptide or a processing artifact of the blood extraction protocol. However, its detection in multiple tissues by multiple groups, and the saturable BBB transport mechanism, argue against pure artifact.

What this means for users: DSIP's biological activities are real—they have been replicated in multiple labs. But without knowing how the body makes and regulates DSIP, we cannot understand how exogenous DSIP integrates with the body's own signaling. We are injecting a molecule whose basic biology is unknown.

Claims vs. Evidence

We currently don’t have any vetted partners for this compound. Check back soon.

The Human Evidence Landscape

Schneider-Helmert (1987) — Double-Blind Insomnia Study

Design: Placebo-controlled, double-blind. N=14 middle-aged chronic insomniacs. IV DSIP for 7 successive nights. Polysomnography at baseline, during treatment, and post-treatment. PMID 3622582.

Findings: Sleep substantially improved from first dose. Additional improvement with repeated doses. Sleep efficiency and daytime rest reached normal control levels. Daytime alertness and performance significantly increased. Effects maintained for the first post-treatment night.

Limitations: N=14. IV administration (impractical for chronic use). 1987 methodology. Single site. Never replicated.

Bes et al. (1992) — Double-Blind Insomnia Study

Design: Double-blind, matched-pairs, parallel-groups. N=16 chronic insomniacs. IV DSIP (25 nmol/kg) vs. placebo (glucose). PMID 1299794.

Findings: Higher sleep efficiency and shorter sleep latency with DSIP vs. placebo. However, "statistically significant effects were weak and in part could be due to incidental change in the placebo group." The study's own conclusion: "short-term treatment of chronic insomnia with DSIP is not likely to be of major therapeutic benefit."

Dick et al. (1984) — Addiction Withdrawal Study

Design: Open-label, uncontrolled. N=107 inpatients (60 opiate-dependent, 47 alcohol-dependent). IV DSIP. PMID 6548969.

Findings: 97% of opiate-dependent patients: symptoms disappeared or markedly improved. 87% of alcohol-dependent patients: symptoms alleviated.

Limitations: No control group. No blinding. Addiction withdrawal has high placebo response rates. Never replicated.

Schneider-Helmert (1981) — Early Sleep Study

Design: DSIP in subjects with disturbed sleep. PMID 7028502.

Findings: Subjects immediately reported "sleep pressure." Sleep increased by 59% within 130 minutes vs. placebo.

The Evidence Gap

All human data is from the 1980s–1990s. No modern trial with contemporary methodology has been conducted. The most recent significant publication is a 2006 review—which concluded that the basic science is unresolved. DSIP research has essentially ceased.

Safety, Risks, and Limitations

No Significant Adverse Effects Reported

Across all published human studies, DSIP was well-tolerated. Occasional transient headache, nausea, and vertigo were reported.

Short Half-Life and Stability Concerns

DSIP is rapidly degraded by aminopeptidases in plasma. Subcutaneous administration (as used in community protocols) may have very different bioavailability than IV (as used in all clinical trials). The efficacy of subcutaneous DSIP has never been studied.

No Long-Term Safety Data

No adequate long-term safety study exists. All human data comes from short-term administration.

No Drug Interaction Data

No formal drug interaction studies have been conducted.

Route Mismatch

All published human efficacy data used IV administration. The community uses subcutaneous injection. The bioavailability difference is unknown and potentially significant given DSIP's rapid plasma degradation.

Legal and Regulatory Status

Worldwide: Not approved in any country. No IND filed. No active regulatory development.

Historical: Deltaran (a Russian DSIP preparation) was available as a pharmaceutical but has been discontinued.

Legal status: Research chemical. Available from peptide vendors.

Research Protocols and Formulation Considerations

Clinical Formulation (Historical)

All clinical trials used DSIP in aqueous IV infusion. No standardized pharmaceutical formulation is currently manufactured.

Research Chemical Availability

Available as lyophilized powder from peptide vendors. Reconstituted in bacteriostatic water for subcutaneous injection (community use).

Stability Concerns

DSIP is highly susceptible to aminopeptidase degradation. Reconstituted solutions should be used promptly or stored refrigerated for short periods.

Dosing in Published Research

Published Clinical Dosing

Key Points

• All published human data used intravenous administration
• The Bes et al. dose (25 nmol/kg) translates to approximately 21 mcg/kg or ~1.5 mg for a 70 kg person
• No dose-ranging study has been published
• No subcutaneous pharmacokinetic data exists

Dosing in Self-Experimentation Communities

The peptide community uses DSIP primarily for sleep optimization, administered by subcutaneous injection before bedtime. Typical community dosing ranges from 100–300 mcg SC, though this is entirely anecdotal—no published human PK/PD data informs subcutaneous dosing.

Community protocols vary widely, with some users dosing nightly and others cycling (e.g., 5 days on, 2 days off). Subjective reports include improved sleep quality, faster sleep onset, and more vivid dreams. Some users report diminishing effects with continued use, though the clinical literature found no tolerance in the short trials conducted.

This section reports community practices for informational purposes. These protocols have not been validated in controlled trials.

Combination Stacks

Research into DSIP combination protocols is limited. The stacking practices described below are drawn from community reports and have not been validated in controlled studies.

If you are considering combining DSIP with other compounds, consult a qualified healthcare provider. Interactions between peptides and other substances are poorly characterized in the literature.

Frequently Asked Questions

Summary of Key Findings

DSIP is a scientific curiosity that has outlasted the research programs that studied it. Discovered in 1977, it has genuine pharmacological activities—endogenous opioid release, cortisol suppression, antioxidant upregulation—confirmed across multiple independent labs. It has better human data than most peptides in the nootropic market: two double-blind sleep studies and a striking (if unblinded) addiction withdrawal study. It is endogenous—your body makes it, though nobody knows how.

The problems are equally real. The basic molecular biology is unresolved after nearly fifty years—no gene, no receptor, no precursor protein. The sleep trials are small and old, and one of the two concluded DSIP is "not likely to be of major therapeutic benefit." The addiction data is uncontrolled. All human data used IV administration, while the community uses subcutaneous injection with unknown bioavailability. Research has essentially stopped.

For the community, DSIP is a compound with genuine but modest evidence for sleep improvement—better supported than most peptide sleep aids, but far short of what would be considered clinical evidence by modern standards. The fifty-year mystery makes it endlessly interesting. The thin evidence makes it a genuine eyes-open proposition.

Verdict Recapitulation

DSIP has human trial data (including two RCTs) that most peptide nootropics would envy. But that data is decades old, the basic molecular biology is unresolved, and the leading review calls the sleep hypothesis "weak." Eyes open—the evidence is real but aging, and the science beneath it is one of neuroscience's most enduring unsolved puzzles.

For readers considering DSIP, the evidence above represents the current state of knowledge. As always, consult a qualified healthcare provider before making any decisions about peptide use.

Where to Source DSIP

Further Reading and Resources

If you want to go deeper on DSIP, the evidence landscape for cognitive & neuroprotective peptides, or the methodology behind how we evaluate this research, these are the places worth your time.

ON PEPTIDINGS

• Cognitive & Neuroprotective Research Hub — Overview of all compounds in this cluster
• Reconstitution Guide — How to properly prepare injectable peptides
• Storage and Handling Guide — Proper storage to maintain peptide stability
• About Peptidings — Our editorial methodology and evidence framework

EXTERNAL RESOURCES

• PubMed: DSIP — All indexed publications
• ClinicalTrials.gov — Active and completed trials

Selected References and Key Studies

1. Schneider-Helmert D, Schoenenberger GA. "Effects of DSIP in man: multifunctional psychophysiological properties." European Archives of Psychiatry and Neurological Sciences, 237(1), 23–30 (1987). PMID 3622582
2. Bes A, Guilhaume A, Séquela P, et al. "Repeated treatment with DSIP in chronic insomnia." Neuropsychobiology, 26(4), 193–196 (1992). PMID 1299794
3. Dick P, Grandjean ME, Bandle EF, et al. "DSIP in the treatment of withdrawal syndromes from alcohol and opiates." European Neurology, 23(6), 364–371 (1984). PMID 6548969
4. Schneider-Helmert D, Schoenenberger GA. "The influence of synthetic DSIP (delta-sleep-inducing-peptide) on disturbed human sleep." Experientia, 37(9), 913–917 (1981). PMID 7028502
5. Kastin AJ, Banks WA, Zadina JE, Graf MV. "Brain peptides: the dangers of neglect." Molecular Neurobiology, 9(1–3), 1–15 (1984). PMID 6547363
6. Kovalzon VM, Strekalova TV. "Delta sleep-inducing peptide (DSIP): a still unresolved riddle." Journal of Neurochemistry, 97(2), 303–309 (2006). PMID 16539679
7. Nakamura A, Nakashima M, Sugao T, et al. "Delta sleep-inducing peptide stimulates the release of immunoreactive met-enkephalin from rat brainstem slices." Brain Research, 479(1), 174–178 (1989)

---